一项人群数据库分析:估计2004至2022年高疫苗接种覆盖率地区14岁以下儿童的水痘疫苗有效性
在意大利威尼托地区,2007年起实施两剂次水痘疫苗普遍接种,2019年覆盖率达90%。该回顾性分析利用Pedianet家庭儿科医生数据库,纳入2004年1月至2022年4月出生或入组的14岁以下儿童,评估水痘疫苗有效性。结果显示,接种一剂和两剂的水痘疫苗有效性分别为83.4%和94.7%,突破性病例罕见。
要点
- 接种一剂和两剂水痘疫苗的有效性分别为83.4%和94.7%。
- 未接种儿童6年累积水痘发生概率为10.7%,接种一剂和两剂分别为2.5%和0.4%(log-rank检验,p < 0.001)。
- 突破性水痘病例仅35例,并发症13例,均属罕见事件。
核心结论
- 两剂次水痘疫苗接种方案能有效大幅减少水痘病例,突破性水痘事件仍属罕见。
研究设计与样本
- 回顾性分析,使用意大利威尼托地区73名家庭儿科医生组成的Pedianet综合数据库。
- 纳入2004年1月至2022年4月期间从出生起入组的14岁以下儿童,共36,498名,随访233,508人年。
- 病例定义为接种水痘疫苗后超过42天发生的突破性病例。
- 采用Kaplan-Meier曲线和log-rank检验比较不同接种状态下的水痘发病率,并用Cox回归估计调整性别、接种状态、年龄组、早产和社会经济状态后的风险比(aHR),疫苗有效性定义为1-aHR。
主要发现
- 共发生1006例水痘病例,其中13例有并发症,35例为突破性病例。
- 无论接种状态如何,年龄较小儿童的水痘风险高于7岁以上儿童:未接种儿童中,<12月龄 vs 5-6岁儿童的发病率分别为5.5 vs 19.5×1000人年;接种儿童中分别为1.1 vs 5.4×1000人年。
- 接种一剂和两剂水痘疫苗的有效性分别为83.4%和94.7%。
- 6年后,未接种儿童、接种一剂和接种两剂儿童的累积水痘发生概率分别为10.7%、2.5%和0.4%(log-rank检验,p < 0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In the Veneto Region of Italy, universal varicella vaccination (VV) started in 2007 with a two-dose schedule at 12-15 months and 5-6 years of age achieving 90 % coverage in 2019. The study aimed at evaluating the vaccine effectiveness (VE) in children using a primary-care database METHODS: This retrospective analysis used Pedianet, a comprehensive database of 73 family paediatricians in the Veneto Region. Incidence rates (IR) of varicella were evaluated in children aged <14 years enrolled since birth, between January 2004 to April 2022. Cases were classified as breakthrough if happening beyond 42 days post-VV. Complications and prescription were evaluated. Subject were followed up from 2004 or the enrollment date, until the end of assistance/study or the first or second VV dose. Kaplan-Meier curves and log-rank tests were used to compare the varicella incidence by vaccination status. Hazard ratios of varicella infection, adjusted (aHRs) for sex, vaccinal status, age group, prematurity and socioeconomic status were estimated with Cox's regression. VE for one and two VV doses was defined as 1-aHR*. RESULTS: 36,498 children, followed for 233,508 person-years from 2004 to 2022 experienced 1006 cases of varicella (13 complicated and 35 breakthrough). Younger children had a higher risk of experiencing varicella compared to children aged >7 years, irrespective of their vaccination status. Indeed, the IR increased from 5.5 to 19.5 × 1000 person-years and from 1.1 to 5.4 × 1000 person-years in unvaccinated and vaccinated children aged <12 months versus those aged 5-6 years, respectively. Varicella VE was 83.4 % and 94.7 % in those vaccinated with one and two doses. After six years, the cumulative probability of experiencing varicella was 10.7 % for unvaccinated subjects, and 2.5 % and 0.4 % for those vaccinated with one and two-doses (log-rank test, p < 0.001). CONCLUSIONS: Two-dose schedule VV is effective in drastically reduce varicella episodes. Breakthrough varicella episodes remain rare events.
引用
- Barbieri E, Cocchio S, Furlan P, et al. A population database analysis to estimate the varicella vaccine effectiveness in children < 14 years in a high vaccination coverage area from 2004 to 2022. Vaccine. 2024. PMID: 39332238. doi:10.1016/j.vaccine.2024.126387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。